Patisiran
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis
Trial Timeline
Jul 16, 2015 → Nov 23, 2022
NCT ID
NCT02510261About Patisiran
Patisiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02510261. Target conditions include Amyloidosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
20 competing products in Amyloidosis